| Authors: |
Agrawal L; Biorepositories and Biospecimen Research Branch (BBRB), Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD., Moore HM; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Engel KB; GAP Solutions Inc, Herndon, VA., Greytak SR; Kelly Government Solutions, Rockville, MD., Tam AL; Department of Interventional Radiology, Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, TX., Killian JK; Foundation Medicine, Cambridge, MA., Merrick DT; Department of Pathology, Anschutz Medical Campus, University of Colorado, Aurora, CO., Parchment RE; Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; Department of Pathology, City of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD. |
